Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Cary Pfeffer
AddedMar 31, 2024
UpdatedMay 31, 2026
Cary Pfeffer

Cary Pfeffer

Board Member, Tango Therapeutics

Crunchbase

Cary Pfeffer's Career

Tango Therapeutics
Tango Therapeutics

Boston, MA, US

Board Member· Board
Faze Medicines
Faze Medicines

Cambridge, MA, US

Board Member· Board
Rheos Medicines
Rheos Medicines

Cambridge, MA, US

Board Member· Board
Edimer Pharmaceuticals
Edimer Pharmaceuticals

Cambridge, MA, US

Board Member· Board
Casma Therapeutics
Casma Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Cary Pfeffer's Career

Tango Therapeutics
Tango Therapeutics
Public$351M1102017Boston, MA, US
Board Member· Board

Leadership at Tango Therapeutics

Barbara WeberBarbara WeberBoard Member
José BaselgaJosé BaselgaCo-Founder
Timothy LuTimothy LuCo-Founder
William G. KaelinWilliam G. KaelinBoard Member
Alexis BorisyAlexis BorisyBoard Member
Antoni RibasAntoni RibasBoard Member

Similar to Tango Therapeutics

Marengo TherapeuticsMarengo TherapeuticsCambridge, MA, USCancer Treatmentest. 2015Marengo TherapeuticsCambridge, MA, US · est. 2015

Marengo Therapeutics: A clinical-stage biotech company dedicated to improving patient lives.

Series B · $80M36
GO TherapeuticsGO TherapeuticsCambridge, MA, USCancer Therapiesest. 2014GO TherapeuticsCambridge, MA, US · est. 2014

GO Therapeutics, Inc.: A US-based biotech firm specializing in cancer-specific immunotherapies and drugs.

Series A · $5M11
TG TherapeuticsTG TherapeuticsNew York City, NY, USCancer Treatments, Pharmaceuticalsest. 1993TG TherapeuticsNew York City, NY, US · est. 1993

TG Therapeutics: A biopharmaceutical firm innovating cancer treatments, focusing on non-Hodgkins lymphoma.

Public · $205M226
Window TherapeuticsWindow TherapeuticsBoston, MA, USCancer Treatmentest. 2021Window TherapeuticsBoston, MA, US · est. 2021

Window Therapeutics: A biotech firm innovating targeted cancer treatments for unmet patient needs.

Angel · $256k4
Faze Medicines
Faze Medicines
Series A$81M402020Cambridge, MA, US
Board Member· Board

Leadership at Faze Medicines

Philip VickersPhilip VickersCEO
Charles HomcyCharles HomcyBoard Member
Laura BrassLaura BrassBoard Member
Ron ValeRon ValeCo-Founder
J. Paul TaylorJ. Paul TaylorCo-Founder
Roy ParkerRoy ParkerCo-Founder
Rheos Medicines
Rheos Medicines
Series A$60M332018Cambridge, MA, US
Board Member· Board

Leadership at Rheos Medicines

Erika PearceErika PearceCo-Founder
Abbie CelnikerAbbie CelnikerBoard Member
Barbara FoxBarbara FoxCEO
Edward PearceEdward PearceCo-Founder
Kathleen Sereda GlaubKathleen Sereda GlaubBoard Member
John Duncan HiggonsJohn Duncan HiggonsBoard Member
Edimer Pharmaceuticals
Edimer Pharmaceuticals
Series B$40M142009Cambridge, MA, US
Board Member· Board

Leadership at Edimer Pharmaceuticals

Neil KirbyNeil KirbyBoard Member
Bill AliskiBill AliskiBoard Member

Similar to Edimer Pharmaceuticals

Edison PharmaceuticalsEdison PharmaceuticalsMountain View, CA, USDrug Developmentest. 2005Edison PharmaceuticalsMountain View, CA, US · est. 2005

Edison Pharmaceuticals, based in Mountain View, US, develops treatments for rare and neglected diseases.

Series D · $90.6M125
Empire BiotechnologiesEmpire BiotechnologiesSan Francisco, CA, USTherapeuticsest. 2013Empire BiotechnologiesSan Francisco, CA, US · est. 2013

Empire Biotechnologies: Innovating therapies for unmet medical needs, focusing on malabsorption diseases.

Pre-Seed · $1.1M1
Edgemont PharmaceuticalsEdgemont PharmaceuticalsAustin, TX, USPharmaceuticalsest. 2015Edgemont PharmaceuticalsAustin, TX, US · est. 2015

Edgemont Pharmaceuticals, LLC: Manufacturing and processing therapeutic drugs for mental health and menopause.

Series A · $9.8M11
Emerald Health PharmaceuticalsEmerald Health PharmaceuticalsSan Diego, CA, USMedicine, Pharmaceuticalsest. 2017Emerald Health PharmaceuticalsSan Diego, CA, US · est. 2017

Emerald Heath Pharmaceuticals: Innovating cannabinoid-based medicines for incurable diseases.

Public · $300k17
Casma Therapeutics
Casma Therapeutics
Series C$154.9M302018Cambridge, MA, US
Board Member· Board

Leadership at Casma Therapeutics

Frank GentileFrank GentileBoard Member
Beth LevineBeth LevineCo-Founder
Millie RayMillie RayBoard Member
Robert TepperRobert TepperBoard Member
Keith DionneKeith DionneBoard Member
Hiromichi KimuraHiromichi KimuraBoard Member

Cary Pfeffer's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Cary Pfeffer

Tom WoiwodeTom WoiwodeBoard Member · Tempest TherapeuticsChris WilfongChris WilfongCo-Founder · 76BioAsh KhannaAsh KhannaBoard Member · Pivotal bioVenture Partners